Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?

There are few clinical data on the sequential use of aromatase inhibitors (AI). This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR). who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ).

Data di pubblicazione: 2001
Titolo: Formestane, a steroidal aromatase inhibitor after failure of non-steroidal aromatase inhibitors (anastrozole and letrozole): is a clinical benefit still achievable?
Autori: Carlini, P; Frassoldati, Antonio; De Marco, S; Casali, A; Ruggeri, E. M; Nardi, M; Papaldo, P; Fabi, A; Paoloni, F; Cognetti, F.
Rivista: ANNALS OF ONCOLOGY
Parole Chiave: Adult; Aged; Androstenedione; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Disease Progression; Enzyme Inhibitors; Female; Humans; Middle Aged; Nitriles; Postmenopause; Receptors, Estrogen; Retrospective Studies; Treatment Failure; Triazoles; Aromatase Inhibitors
Abstract: There are few clinical data on the sequential use of aromatase inhibitors (AI). This paper focuses on the relevance of clinical benefit CB (CR + PR + SD > or = 6 months) in postmenopausal metastatic breast cancer (MBC) patients treated with the steroidal aromatase inhibitor (SAI) formestane (FOR). who had already received non-steroidal aromatase inhibitor (nSAI): letrozole (LTZ) or anastrozole (ANZ).
Digital Object Identifier (DOI): 10.1023/A:1013180214359
Handle: http://hdl.handle.net/11392/2377871
Appare nelle tipologie:03.1 Articolo su rivista

File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
 
 
 
Powered by IRIS-about IRIS-Utilizzo dei cookie
Logo CINECA  Copyright © 2022